Federal: Other MH Policy
Official titleSubstance Use Disorders Treatment Options
Federal · Relevance score 20 of 100 (tangential). low impact.
This summary is informational and is not legal advice. Read the source text before acting on it.
What this policy change does.
- Jurisdiction
- Federal
- Published
- January 21, 2025
- Impact score
- 20 of 100, from analysis of the full text: tangential
- Primary source
- SAMHSA
Impact on your practice
This is educational content for patients and the general public, not a policy change affecting therapist practice. It may help with patient education and referrals, but does not impact billing, licensing, or regulatory requirements.
Key facts
- SAMHSA educational page on SUD treatment options and definitions
- Part of broader SUD Treatment Month awareness push
- Focuses on public education rather than policy or practice change
- Covers different treatment modalities and recovery pathways
What it would mean for a practice.
This SAMHSA educational resource does not create new regulatory obligations, billing requirements, or documentation standards for your practice. However, it reinforces the clinical and epidemiological foundation underlying increased payer scrutiny of SUD treatment across all mental health modalities. The document confirms that 48.5 million Americans (17% of the population) had a SUD in 2023, establishing the prevalence baseline that justifies insurance companies' prior authorization protocols and medical necessity requirements for substance use-related treatment. As a therapist, you should recognize that payers increasingly expect you to articulate how behavioral therapy integrates with medication-assisted treatment (MAT)—the document emphasizes that FDA-approved medications for alcohol, opioid, and tobacco use disorders work best "in combination with counseling, other behavioral therapies, and recovery supports." This means your treatment plans for SUD cases should explicitly document the medication status of patients (whether they are on buprenorphine, naltrexone, methadone, or FDA-approved alcohol medications) and describe your therapeutic role in that multidisciplinary context. Your documentation should reflect awareness that SUDs are "long-term health conditions that can carry risk of recurrence even after years of recovery"—language that justifies extended or resumed treatment episodes and helps counter insurer denials based on perceived treatment completion. The reference to DSM-5 criteria and severity determination (mild, moderate, severe based on symptom count) confirms that payers will expect you to document the specific number of diagnostic criteria present to establish medical necessity for the intensity and frequency of your services.
Background
SAMHSA launched "SUD Treatment Month" in January 2025 as part of a sustained federal effort to normalize substance use disorder treatment and increase treatment-seeking behavior. This initiative reflects broader policy recognition that SUDs remain undertreated despite high prevalence—the document notes that 17% of Americans had a SUD in the past year. The emphasis on the biopsychosocial model (genetics accounting for 50% of risk, combined with trauma and environmental factors) and the explicit validation of medication-assisted treatment alongside behavioral therapy represents the federal government's alignment with evidence-based practice standards. For therapists, this context matters because it signals that federal agencies continue to prioritize SUD treatment expansion, which will likely drive ongoing pressure on insurance companies to expand coverage and reduce barriers. Simultaneously, the emphasis on "combination" approaches—medications plus therapy—means payers will increasingly scrutinize whether your therapy is evidence-based and directly integrated with pharmacological treatment, not standalone.
What you should do
- Audit your current SUD patient documentation to ensure you explicitly document each patient's medication status (whether on MOUD, MAUD, or no pharmacotherapy) and describe how your behavioral therapy complements or supports that medication plan. Payers use this integration as a marker of medical necessity.
- Review the DSM-5 diagnostic criteria for all 10 classes of SUDs recognized in the document (alcohol, caffeine, tobacco, cannabis, opioids, stimulants, hallucinogens, inhalants, sedatives, hypnotics) and confirm your intake assessments capture the specific symptom count to establish severity level. This determines what intensity of treatment payers will authorize.
- Create or update patient education materials referencing FindTreatment.gov and FindSupport.gov so you can confidently refer patients to SAMHSA's locator tool and explain that combined medication and therapy approaches are evidence-based. This improves treatment engagement and reduces your liability if patients drop out.
- When appealing SUD-related insurance denials, cite the document's statement that "research shows that many people with SUDs respond well to combinations of behavioral therapies, medications, and recovery supports" and that SUDs carry "risk of recurrence even after years of recovery"—this language directly counters denials based on treatment duration limits or perceived treatment completion.
- If your practice serves patients in early recovery or with co-occurring mental health conditions (depression, anxiety), document the elevated risk factors mentioned in this material to justify continued or preventive therapy even when acute symptoms appear stable, since the document emphasizes that SUDs are chronic conditions.
Notable excerpts
"Research shows that many people with SUDs respond well to combinations of behavioral therapies, medications, and recovery supports." (SAMHSA, January 2025) — Use this when justifying therapy alongside medication-assisted treatment in prior authorization requests.
"SUDs are often long-term health conditions that can carry risk of recurrence even after years of recovery." (SAMHSA, January 2025) — Reference this language when appealing denials that limit therapy duration or question the need for resumed treatment.
"In 2023, 48.5 million people 12 or older, or 17 percent of the U.S. population, had a SUD within the past year" (SAMHSA National Survey on Drug Use and Health, 2023) — Cite this prevalence data when advocating for parity enforcement or expanded insurance coverage.
View full source text
Read the original policy source.
Primary source text, linked directly.
https://www.samhsa.gov/blog/substance-use-disorders-treatment-options
- Analysis by
- Therapy Companion policy engine
- Confidence
- high
- Analyzed
- July 28, 2026
Related policy changes.
- Relevance score78 / 100
[US] SB4754: Primary and Behavioral Health Care Access Act of 2026
This federal bill could reshape behavioral health workforce, reimbursement, or access policy nationwide. Both chambers now have versions in committee—therapists should track this closely as it progresses.high impact - Relevance score75 / 100
STAT+: HHS presses ahead with effort to curb antidepressant use
Incoming federal clinical guidance on deprescribing could reshape how therapists collaborate with prescribers, increase referrals for therapy-based alternatives, and potentially create new practice opportunities—or reduce medication management referrals. Early insight into this guidance development is critical for practice planning.high impact - Relevance score72 / 100
Opinion: MAHA is rewriting the vocabulary of American mental health care
If HHS-promoted deprescribing becomes standard practice guidance, therapists may see shifts in referral patterns, patient expectations around medication, and potential new billing codes for medication management/tapering counseling. This represents a major philosophical shift in federal mental health approach.high impact - Relevance score72 / 100
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This omnibus bill has potential to reshape Tennessee's mental health landscape across multiple domains. Therapists should monitor committee review closely, as the 10 amended title sections suggest changes to licensing, insurance, workforce development, or scope of practice.high impact
Track what affects your practice.
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.